APA (7th ed.) Citation

McDade, E., Cummings, J. L., Dhadda, S., Swanson, C. J., Reyderman, L., Kanekiyo, M., . . . Bateman, R. J. (2022). Lecanemab in patients with early Alzheimer’s disease: Detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer's research & therapy, 14(1), 191-17. https://doi.org/10.1186/s13195-022-01124-2

Chicago Style (17th ed.) Citation

McDade, Eric, et al. "Lecanemab in Patients with Early Alzheimer’s Disease: Detailed Results on Biomarker, Cognitive, and Clinical Effects from the Randomized and Open-label Extension of the Phase 2 Proof-of-concept Study." Alzheimer's Research & Therapy 14, no. 1 (2022): 191-17. https://doi.org/10.1186/s13195-022-01124-2.

MLA (9th ed.) Citation

McDade, Eric, et al. "Lecanemab in Patients with Early Alzheimer’s Disease: Detailed Results on Biomarker, Cognitive, and Clinical Effects from the Randomized and Open-label Extension of the Phase 2 Proof-of-concept Study." Alzheimer's Research & Therapy, vol. 14, no. 1, 2022, pp. 191-17, https://doi.org/10.1186/s13195-022-01124-2.